Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary IgAN”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Looking for participantsNCT06676384
What this trial is testing

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Who this might be right for
IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India 585
Early research (Phase 1)Study completedNCT04887532
What this trial is testing

A Trial of HR19042 Capsule in Healthy Chinese Subjects

Who this might be right for
Primary IgA Nephropathy
Jiangsu HengRui Medicine Co., Ltd. 12
Very early researchNot Yet RecruitingNCT06690359
What this trial is testing

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Who this might be right for
IgA NephropathyMembranous Nephropathy
Beijing Immunochina Medical Science & Technology Co., Ltd. 12
Testing effectiveness (Phase 2)Ended earlyNCT05847920
What this trial is testing

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07773727
What this trial is testing

Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

Who this might be right for
Immunoglobulin A Nephropathy (IgAN)
argenx 120
Testing effectiveness (Phase 2)Looking for participantsNCT07182227
What this trial is testing

PS-002 for the Treatment of IgA Nephropathy in Adults

Who this might be right for
Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited 32
Testing effectiveness (Phase 2)Study completedNCT06670352
What this trial is testing

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Who this might be right for
IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd. 87
Large-scale testing (Phase 3)Looking for participantsNCT06858319
What this trial is testing

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Who this might be right for
Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis Pharmaceuticals 220
Testing effectiveness (Phase 2)Looking for participantsNCT06983028
What this trial is testing

Atacicept in Multiple Glomerular Diseases

Who this might be right for
pMNIgANNephrotic Syndrome+2 more
Vera Therapeutics, Inc. 250
Large-scale testing (Phase 3)Study completedNCT05534919
What this trial is testing

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Who this might be right for
Primary Immunoglobulin a Nephropathy (IgAN)
Everest Medicines (Singapore) Pte. Ltd. 21
Not applicableUnknownNCT02712697
What this trial is testing

Integrative Medicine of IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Shanghai University of Traditional Chinese Medicine 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06687174
What this trial is testing

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Who this might be right for
IgA Nephropathy (IgAN)
Wuhan Createrna Science and Technology Co., Ltd 72
Testing effectiveness (Phase 2)Study completedNCT06137768
What this trial is testing

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

Who this might be right for
Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd. 123
Post-approval studies (Phase 4)Study completedNCT02351752
What this trial is testing

Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study

Who this might be right for
Primary IgA Nephropathy
LLiu 20
Post-approval studies (Phase 4)Ended earlyNCT02523768
What this trial is testing

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

Who this might be right for
GlomerulonephritisIgAN
Centre Hospitalier Universitaire de Saint Etienne 117
Large-scale testing (Phase 3)Looking for participantsNCT07498335
What this trial is testing

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Who this might be right for
Berger DiseaseBergers DiseaseIgA Nephropathy+3 more
Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Looking for participantsNCT07305974
What this trial is testing

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

Who this might be right for
IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. 30
Not applicableStudy completedNCT00521508
What this trial is testing

Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy

Who this might be right for
Glomerulonephritis, IGA
Centre Hospitalier Universitaire de Saint Etienne 45
Large-scale testing (Phase 3)Active Not RecruitingNCT05799287
What this trial is testing

Telitacicept for IgA Nephropathy (TELIGAN)

Who this might be right for
Primary IgA Nephropathy
RemeGen Co., Ltd. 318
Not applicableLooking for participantsNCT06676007
What this trial is testing

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

Who this might be right for
IgA Nephropathy (IgAN)Early Initial Therapy
Sichuan Provincial People's Hospital 200
Next Page